Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Seagen, Inc.
Scientific Title
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer